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Purpose: A phase 2 protocol was designed and implemented to assess the toxicity and efﬁcacy of
hypofractionated image guided intensity modulated radiation therapy (IG-IMRT) combined with
low-dose rate 103Pd prostate seed implant for treatment of localized intermediate- and high-risk
adenocarcinoma of the prostate.
Methods and materials: This is a report of an interim analysis on 24 patients enrolled on an
institutional review boardeapproved phase 2 single-institution study of patients with intermediate-
and high-risk adenocarcinoma of the prostate. The median pretreatment prostate-speciﬁc antigen
level was 8.15 ng/mL. The median Gleason score was 4 þ 3Z 7 (range, 3 þ 4Z 7 - 4 þ 4Z 8),
and the median T stage was T2a. Of the 24 patients, 4 (17%) were high-risk patients as deﬁned by
the National Comprehensive Cancer Network criteria, version 2016. The treatment consisted of
2465 cGy in 493 cGy/fraction of IG-IMRT to the prostate and seminal vesicles. This was followed
by a 103Pd transperineal prostate implant boost (prescribed dose to 90% of the prostate volume of
100 Gy) using intraoperative planning. Five patients received neoadjuvant, concurrent, and
adjuvant androgen deprivation therapy.
Results: The median follow-up was 18 months (range, 1-42 months). The median nadir prostate-
speciﬁc antigen was 0.5 ng/mL and time to nadir was 16 months. There was 1 biochemical failure
associated with distant metastatic disease without local failure. Toxicity (acute or late) higher than
grade 3 was not observed. There was a single instance of late grade 3 genitourinary toxicity
secondary to hematuria 2 years and 7 months after radiation treatment. There were no other grade 3
gastrointestinal or genitourinary toxicities.Conﬂicts of interest: None.
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IMRT and low-dose-rate brachytherapy boost are favorable. Longer follow-up is needed to conﬁrm
safety and effectiveness.
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Conventional treatment options for patients with
localized intermediate- to high-risk adenocarcinoma of
the prostate include radical prostatectomy, external beam
radiation therapy (EBRT), interstitial brachytherapy with
or without EBRT, and expectant management.1 Patients
with higher risk disease may be treated with androgen
deprivation therapy (ADT) in the neoadjuvant, concur-
rent, and oftentimes adjuvant setting.
Dose escalation with radiation therapy has been
associated with improved biochemical outcomes.2-5 The
concern with dose escalation is the potential for
increased normal tissue toxicities. EBRT using image
guided intensity modulated radiation therapy (IG-IMRT)
in combination with prostate seed implant boost has
been used in the setting of dose escalation while
attempting to minimize normal tissue toxicity.6 Low-
dose-rate (LDR) prostate seed implant allows for a
conformal dose delivery over several months. EBRT
with IG-IMRT provides dose to the prostate capsule,
seminal vesicles with a margin of 5 to 8 mm, an area at
risk for disease spread that is not routinely covered by
brachytherapy alone.6
The typical dose of radiation therapy delivered in
combination with seed implant is 4500 cGy of IMRT in 25
fractions. This regimen is generally well-tolerated and
effective, and the National Comprehensive Cancer
Network (NCCN) guidelines also recommends this treat-
ment option for intermediate- and high-risk cancers.7-17
However, a drawback for patients is the 5-week duration
of IMRT, which is time-consuming, relatively expensive,
and can be logistically prohibitive for some patients.
Because of advances in imaging and IMRT technol-
ogy, improved treatment precision is possible, allowing
for safe delivery of hypofractionated doses of radiation
therapy. Several studies have demonstrated that the
alpha-beta ratio for prostate cancer may be as low as 1 to
3 Gy, reﬂecting the slow proliferation rate of prostate
cancer.7,18-22 In addition, the alpha-beta ratio does not
alter signiﬁcantly with the diagnostic risk level.23 It is
proposed that, because the alpha-beta ratio of prostate
cancer appears to be similar to or lower than the sur-
rounding normal tissues, there may be an increased
therapeutic ratio with higher doses per fraction.24 Current
radiation therapy treatment regimens using moderatelyhypofractionated radiation therapy for prostate cancer in
randomized trials typically deliver IMRT in 240 to 400
cGy/fraction over 4 to 6 weeks.25-31 These moderately
hypofractionated regimens have been reported to have
similar toxicity and effectiveness compared with con-
ventional IMRT (180-200 cGy/fraction).17 More recently,
studies have assessed “extreme” hypofractionation (500-
725 cGy/fraction) using stereotactic body radiation ther-
apy (SBRT) for 5 days of treatment. Single institution
series have showed similar efﬁcacy and safety when
compared with conventional treatment.32-37 In addition, a
pooled analysis of prospective phase 2 clinical trials
showed the 5-year biochemical relapse free survival rate
of 95%, 84%, and 81% for low-, intermediate-, and high-
risk patients, respectively.38 A systematic review of
SBRT reported that this technique is more cost-effective
compared with conventionally fractionated IMRT.39 At
this time, the NCCN guidelines recommend that hypo-
fractionation using SBRT be considered a cautious
alternative in clinics with the technology, physics, and
clinical expertise.17
The current study is designed to evaluate the tolera-
bility and efﬁcacy of a 5-day course of image-guided
IMRT with a dose biologically equivalent to 4500 cGy in
25 fractions, followed by a Pd-103 implant. To our
knowledge this is the ﬁrst study adding LDR prostate
seed implant boost to hypofractionated IMRT to improve
the radiobiologic therapeutic ratio while maintaining
reasonable patient convenience and reducing cost.Methods and materials
Patient selection
The eligibility criteria for the study included patients at
least 18 years of age with a Zubrod Performance Scale
0 to 1 and locally conﬁned adenocarcinoma of the pros-
tate with the following characteristics: clinical stages
T1c-T2b (American Joint Committee on Cancer, 6th
Edition); prostate-speciﬁc antigen (PSA) <10 combined
Gleason score 7; PSA >10 combined Gleason score
6; maximum PSA 20. In addition, the patients had to
have no signiﬁcant obstructive symptoms (goal American
Urological Association [AUA] scores 15), a pre-implant
prostate volume of 60 mL by transrectal ultrasound, and
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study-speciﬁc informed consent form was required before
study entry.
Evaluation
Each patient was evaluated at the multidisciplinary
Allegheny General Hospital Prostate Center by a urologist
and a radiation oncologist. An AUA Symptom Index
form, a Sexual Health Inventory for Men (SHIM) potency
index, and a questionnaire for rectal symptoms and uri-
nary continence was completed by each patient before
treatment. The initial evaluation consisted of a history and
physical examination, digital rectal examination, and a
PSA level. A prostate biopsy was obtained, and the pa-
thology was reviewed by an Allegheny General Hospital
pathologist.
ADT
The addition of ADT was left to the treating physi-
cian’s discretion. The patients receiving ADT were started
at least 2 months before initiation of radiation treatment
and had it continue for a minimum of 4 months. ADT
consisted of a luteinizing hormone-releasing hormone
agonist and/or an antiandrogen approved for the treatment
of adenocarcinoma of the prostate.
Treatment details
Treatment consisted of IG-IMRT to a dose of 2465
cGy in 5 daily fractions at 493 cGy/fraction, which was
followed in 2 to 4 weeks by a permanent Pd-103 seed
implant. Details of the dose calculation are provided in
the Discussion section. The patients underwent a
computed tomography (CT) simulation (3-mm cuts) with
an immobilization device for their lower extremities for
treatment planning. They had a full bladder and empty
rectum for CT simulation and daily treatments. The
clinical target volume included the prostate and the
seminal vesicles. A planning target volume was created
by adding a 5-mm margin in all directions. Acceptable
plans included at least 98% of the planning target vol-
ume covered by the prescription dose and no hot spot
exceeding 5% of the prescribed dose. Most IMRT plans
were designed with 5 in-plane beams and 18-MV ra-
diographs using the Elekta/Xio V 5.1 planning system
(Elekta AB, Stockholm, Sweden). The beams were
placed in a star-shaped pattern, with an anteroposterior
ﬁeld, 2 anterior oblique ﬁelds, and 2 posterior oblique
ﬁelds. The IMRT plans are multileaf collimator-based,
with a step-and-shoot method. The organs-at-risk dose
constraints were the maximum femoral head dose
limited to less than the prescribed dose, rectum V24 <10
mL, and bladder V20 <30%. Image guidance wasperformed daily with megavoltage cone beam CT.
Within 2 to 4 weeks after completion of EBRT, all pa-
tients underwent transperineal prostate seed implantation
under spinal or general anesthesia. Real-time intra-
operative computer-assisted planning with transrectal
ultrasound guidance was used. Pd-103 seeds were used
for all patients. The goal was to deliver a D90 (dose to
90% of the prostate volume) of 100 Gy  20%. The
rectal dose was limited to <0.5 mL of the rectum
receiving a prescription dose. Maximum urethral dose
was limited to <150% of the prescription dose. One
month after the procedure, all patients underwent a
noncontrast CT for postoperative dosimetry and assess-
ment of the implant quality.
Outcomes
The primary endpoint was grade 2 or higher acute and
late genitourinary (GU) and gastrointestinal (GI) toxicities
as well as the time to late grade 3 or higher adverse
events. The secondary endpoints evaluated were
biochemical failure, freedom from failure, local and
regional recurrence, distant metastasis, rate of salvage
ADT, prostate cancer-speciﬁc mortality, and overall sur-
vival. Biochemical failure was based on the Phoenix
deﬁnition of nadir plus 2 ng/mL, without backdating.40
An interim analysis of outcomes was performed at 6
months, 1 year, and 2 years after completion of treatment.
Early stopping criteria were based on whether toxicities
exceeded our historical standards; speciﬁcally, the results
we obtained in the Allegheny General Hospital review of
patients treated with 4500 cGy in 25 fractions of IG-
IMRT followed by seed implant.6 To further assess acute
toxicities, accession to the trial was held from the time the
ﬁrst 12 patients were accrued until they had been followed
for a minimum of 3 months.
Toxicity
The toxicity evaluation was based on the National
Cancer Institute’s Common Terminology Criteria for
Adverse Events, version 4.0. Late toxicity was deﬁned as
more than 360 days from the completion of radiation
treatment. The patients were evaluated for toxicities
weekly on treatment and then in scheduled follow-up as
described later.
Follow-up
All patients were scheduled to be seen in follow-up 1
month after implant and then every 6 months for at least 10
years. At each follow up visit, the patients completed an
AUA form, a SHIM potency index, and a questionnaire for
rectal symptoms and urinary continence. A PSA and rectal
examination were also performed.
Table 1 Patient characteristics (n Z 24)
Parameter Median Range
Age (y) 67 53-75
PSA (ng/ml) 8.15 4.2-20.9
Initial AUA score 6.5 1-20
Initial SHIM score 15 0-24
n %
Gleason score
3 þ 4 Z 7 12 50
4 þ 3 Z 7 10 42
4 þ 4 Z 8 2 8
T stage
T1c 12 50
T2a 11 46
T2b 1 4
NCCN risk group
Intermediate 20 83
High 4 17
Hormonal therapy
Yes 5 21
No 19 79
AUA, American Urological Association; NCCN, National Compre-
hensive Cancer Network; PSA, prostate-speciﬁc antigen; SHIM,
Sexual Health Inventory for Men.
Figure 1 The American Urological Association (AUA) scores
obtained at the follow-up examination after prostate seed
implant, with the pretreatment AUA scores signiﬁed by time 0.
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Statistical analysis was performed with SPSS, version
22.0 (IBM, Chicago, IL).
Results
After informed consent and enrollment on the institu-
tional review boardeapproved protocol, data were
collected prospectively on 24 patients with adenocarci-
noma of the prostate treated at Allegheny General Hos-
pital between July 2011 and August 2015. The median
age of the patients was 67 years (range, 53-75). The
median pretreatment PSA level was 8.15 ng/mL (range,
4.2-20.9). The median Gleason score was 4 þ 3 Z 7
(range, 3 þ 4Z 7 - 4 þ 4Z 8). The Gleason score was 3
þ 4 Z 7 in 12 patients (50%), 4 þ 3 Z 7 in 10 patients
(42%), and 4 þ 4 Z 8 in 2 patients (8%). The median T
stage was T2a. The T stage was T1c in 12 patients (50%),
T2a in 11 patients (46%), and T2b in 1 patient (4%). Of
the 24 patients, 4 (17%) were high-risk patients as deﬁned
by the NCCN criteria, version 2016.17 The median pre-
treatment AUA score was 6.5, with a range of 1 to 20.
The median pretreatment SHIM score was 15, with a
range of 0 to 24, and was completed by 22 of the 24
patients. There were 5 (21%) patients who received ADT
with radiation therapy. Table 1 demonstrates the patient
characteristics. Three of the 4 high-risk patients received
ADT therapy. Two intermediate-risk group patients were
also started on ADT. Leuprolide through an intramuscular
route was the ADT therapy in all patients. One high-risk
patient received Leuprolide 30 mg, starting 4 months
before radiation treatment; however, did not continue with
the recommended adjuvant treatment secondary to cost.
Another high-risk patient received Leuprolide 22.5 mg,
starting 5 months before radiation treatment and
continued it for an additional year. The last high-risk
group patient received Leuprolide 22.5 mg starting
about 2 months before radiation treatment and continues
to receive the ADT, with the last dose scheduled so that
he completes an additional year and 6 months of ADT.
One of the intermediate-risk group patients received
Leuprolide 30 mg starting 5 months before radiation
treatment. Another intermediate-risk group patient
received Leuprolide 22.5 mg, starting about 3 months
before beginning radiation treatment and then refused
additional adjuvant treatment.
All patients completed the treatment, consisting of
daily IG-IMRT to the prostate and seminal vesicles to a
dose of 2465 cGy in 5 fractions, followed by a Pd-103
prostate seed implant. The median prostate seed implant
D90 dose was 106.9 Gy. The median follow-up was 18
months (range, 1-42 months). The median nadir PSA was
0.5 ng/mL, with a range of 0.006 to 5.83 ng/mL. The time
to PSA nadir was 16 months. At the time of analysis, theoverall survival was 100%. There was 1 biochemical
failure associated with distant metastatic disease without
local failure in an intermediate-risk patient, for a
biochemical recurrence-free survival of 96%. The median
AUA scores obtained at the follow-up examinations are
shown in Fig 1.
There were no grade 3 or higher acute GI or GU
toxicities or grade 3 or higher late GI toxicities. There was
1 grade 3 late GU toxicity secondary to hematuria. He
was an intermediate-risk group patient receiving ADT and
had a palladium seed implant dose of 119.7 Gy. He
developed gross hematuria with clots 2 years and 7
months after radiation treatment. He underwent a
cystoscopy and fulguration of 2 hemorrhagic spots in the
Table 2 Grade 2 and Grade 3 GI and GU toxicity classi-
ﬁed by CTCAE 4.0 categories
Toxicity Acute (<12
months)
Late (12
months)
Grade 3 Grade 2 Grade 3 Grade 2
GI
Proctitis 0 0 0 1
Anal hemorrhage 0 1 0 0
Diarrhea 0 1 0 0
Anal ﬁstula 0 0 0 0
Total 0 2 0 1
GU
Urinary urgency 3 1
Urinary frequency 14 11
Hematuria 0 0 1 2
Urinary retention 0 1 0 0
Urinary obstruction 0 0 0 0
Total 0 18 1 14
CTCAE4.0, Common Terminology Criteria for Adverse Events,
version 4.0; GI, gastrointestinal; GU, genitourinary.
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procedure. The total acute and late GI and GU toxicities
classiﬁed by Common Terminology Criteria for Adverse
Events, version 4.0, categories are summarized in Table 2,
and are based on the documented medical record, AUA
form, and the rectal and continence questionnaire.
Given limited patients with a pretreatment SHIM score
12 (representing a SHIM score reﬂectingmild to moderate
erectile dysfunction) and who did not receive ADT, analysis
on maintaining erectile function could not be performed.Discussion
This publication describes the early results of the ﬁrst
clinical trial assessing the toxicity and efﬁcacy of hypo-
fractionated IMRT, 2465 cGy in 5 fractions, followed byTable 3 Schedule for equivalent effects as 4500cGy in 25 days a
Tissue BEDconv
Prostate tumor (a/ß Z 2.0 Gy) 8544cGy2
BEDcGy-conv
Acute-effect tissue at risk
Bladder (a/ß Z 10 Gy) 5310
Rectum (a/ß Z 10 Gy) 5310
Late-effect tissue at risk
Bladder (a/ß Z 3.0 Gy) 7200
Bladder (a/ß Z 5.8 Gy) 5890
Rectum (a/ß Z 3.0 Gy) 7200
Rectum (a/ß Z 3.9 Gy) 6577
BED, biologically effective dose; BEDconv, conventional schedule BED; BED
hypofractionated schedule; Fx, fraction; hypofx, hypofractionated; total doselow-dose rate prostate seed implant in patients with in-
termediate- and high-risk adenocarcinoma of the prostate.
The radiobiologic rationale
In radiation therapy, the alpha-beta (a/ß) ratio is a
measure of the fractionation sensitivity of a particular cell
type. Several studies have demonstrated that the a/ß ratio
for prostate cancer is likely low, between 1 and 3 Gy, in
contrast to most tumors.7,18-22 As a result, hypofractio-
nated regimens may result in improved differential cell
killing between the cancer and surrounding normal
tissues.
To facilitate comparison between the conventional and
hypofractionated schedule for the external beam radiation,
biologically effective doses (BED) were calculated and
the isoeffect model using the linear quadratic equation
was applied. The total dose and dose per fraction in the
hypofractionated schedule was calculated to give an
equivalent prostate dose to 4500 cGy in 25 fractions
(conventional schedule). We assumed the a/ß ratio for
prostate cancer was 2 Gy and calculated the BED2Gy for
the conventional schedule as 85.5 Gy2.
41 Continuing the
model, we determined the hypofractionation total dose
equivalent to 85.5 Gy2 was 24.65 Gy2 with a fraction size
of 4.93 Gy per fraction. The total BED from the combi-
nation of the prostate seed implant (Pd-103 prescribed
dose 100 Gy to the D90, BED 112 Gy2)
41,42 and the
hypofractionated schedule (BED 85.5Gy2) is 197.5 Gy2.
In addition, the maximum biologically effective doses that
could be received by the bladder and rectum in the con-
ventional and hypofractionated schedules were also
calculated. Some literature suggests the a/ß ratio for
late-effect damage to the normal organs at risk (bladder
and rectum) is 3 Gy, whereas others suggest 5.8 Gy and
3.9 Gy for bladder and rectal tissue, respectively.31,43,44
An a/ß ratio of 10 Gy was used for acute tissue
response. Computations given in Table 3 were derived for
each a/ß value for comparison. As demonstrated int 1.8Gy/fx
Total dosehypofx Dose/fx (Gy/fx)
2465cGy 4.93
BEDcGy-hypofx Conventional Hypofx
3682 1.8 4.93
3682 1.8 4.93
6530 1.8 4.93
4562
6530 1.8 4.93
5583
cGy-conv, BED of the conventional schedule; BEDcGy-hypofx, BED of the
hypofx, total dose of hypofractionated schedule.
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bladder and rectum is less than that received under the
conventional schedule. In summary, we calculated a total
dose using a hypofractionated external radiation schedule
that delivers 2465 cGy in 5 days, which should result in
similar prostatic cancer responses as a conventional
schedule of 4500 cGy delivered over 25 days without
compromising acute or late normal tissue reactions.
Dose escalation
In our study, we speculated that dose escalation to a
BED of 197.5 Gy2 with the combined LDR prostate seed
implant and the hypofractionated EBRT may improve
freedom from biochemical failure because randomized
trials suggested that dose escalation is associated with
improved biochemical outcomes.2-5 In a retrospective
review, Stock et al found a signiﬁcant improvement in 10-
year freedom from biochemical failure of 87% with BED
>150 Gy2 compared with 78% with BED 150 Gy2 in
patients receiving ADT. They also reported that with a
BED >200 Gy2, hormonal therapy provided no increased
beneﬁt, though in the highest risk patients, hormone
therapy may still provide a systemic advantage.45 Despite
the dose responsiveness of prostate cancer, dose escala-
tion must be weighed against the potential of increased
toxicity.
Toxicity
At a median follow-up of 18 months, only preliminary
observations can be made. In regards to the GU toxicity,
mild-to-moderate urinary toxicity is seen in most patients
after a prostate seed implant and urinary discomfort
typically lasts several months.46,47 This same pattern was
observed in our cohort of patients with the majority
experiencing grade 2 GU toxicity requiring alpha-
blockers to help alleviate their urinary symptoms. The
increase in urinary symptoms is demonstrated in Fig 1
where the AUA score peaks at 1 month after prostate
brachytherapy. Our acute and late grade 3 GU toxicity is
comparable to the toxicity of conventional fractionated
EBRT treatment combined with a prostate seed implant
boost, with studies reporting acute and late grade 3 GU
toxicities ranging between 1.1% and 12% and 0.8% and
12%, respectively.6,8,13,15,16,19-21 Our study had similar
ﬁndings to these studies as our cohort had no acute grade
3 GU toxicity and a late grade 3 GU toxicity incidence of
4.2%.
With the use of hypofractionation, there is a concern
for an increased late toxicity to the rectum, urethra, and
bladder neck. This is particularly important given that the
rectum is the major dose-limiting organ in the treatment of
prostate cancer. As discussed previously, the a/ß ratio
for the late rectal toxicity may be greater than the 1 to 3Gy a/ß ratio associated with prostate cancer. If this is
indeed the case, then hypofractionation should allow for
an increased tumor effect without an associated increase
in late toxicity. Our study to date shows promising results
with no acute or late grade 3 GI toxicities. In addition, our
toxicity proﬁle is similar when compared with the con-
ventional fractionated EBRT treatment and LDR
brachytherapy boost, with series reporting no acute GI
toxicities and late GI toxicities ranging between 0% and
3%.6,8,14-16,19-21 For comparison, Valakh et al reported no
acute GI toxicity and 3% incidence of late GI toxicity.6
Granted, our follow-up is still early, and as such, longer
follow-up will be needed to conﬁrm the previous ﬁndings.
PSA response and biochemical control
With a median follow-up of 18 months, the results for
PSA response and biochemical control appear consistent
with results seen with standard treatment. There was 1
biochemical failure associated with distant metastatic
disease without local failure. In addition, studies have
demonstrated that the nPSA12 (nadir PSA level achieved
during the ﬁrst year after completing radiation treatment)
is an early predictor of biochemical failure, distant
metastasis, and mortality.48,49 In the publication by Ray
et al, an nPSA12 of 2.0 ng/mL had an 8-year PSA-
disease free survival, distant metastasis-free survival,
and overall survival rate of 55%, 95%, and 73%,
respectively, compared with 40%, 88%, and 69% for
patients with a nPSA12 of >2.0 ng/mL.49 We found that
90% of patients with at least a year follow-up of PSA
levels had a nPSA12 of 2.0 ng/mL.
Conclusion
The early results of our safety and toxicity protocol
consisting of hypofractionated IG-IMRT with an LDR
brachytherapy boost, show this combination to appear to
be, in terms of short-term morbidity, both safe and
effective. The rates of GI and GU toxicities are compa-
rable to reported toxicities of conventional IG-IMRT with
a LDR brachytherapy boost. In addition, the early
biochemical control and PSA response is consistent with
standard treatments; however, the results should be
interpreted cautiously given the short-term follow-up.
This shortened treatment schedule can help improve ac-
cess to health care and reduce cost of therapy. Longer
follow-up is needed to conﬁrm the long-term safety and
efﬁcacy of this approach.
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